Quarterly Activities & Cashflow Report
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
26 July 2022
Quarterly Activity Report Q4 FY22
●
●
●
●
●
●
Sales growth accelerated in Q4 with sales of $1.39m, up 50.3%
Annualised sales of $5.56m based on Q4
Quarterly cash receipts $1.37m, up 92%
Maintained strong gross margins of 58%
Cash balance of $5.5 million as of 30 June 2022
Material distribution agreement signed with Priceline Pharmacy Group
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
company’) is pleased to provide its Appendix 4C and activity report for the quarter
ended 30 June 2022.
Sales Revenue
Sales growth accelerated in Q4 FY22, driven by Biome’s Activated Probiotics® in both
pharmacy and independent practitioner sales channels. Biome recorded increased
net sales to $1.39 million, up 50.3% on the previous quarter. The Q4 result represents
an annualised sales run rate of $5.56 million.
Biome successfully maintained its strong gross margin at 58%, amidst increasing raw
material cost and global logistics challenges.
A key driver of the June quarter sales growth was the expansion of the Activated
Probiotics® product range. Biome launched Biome Baby™ Probiotic in late May 2022
following the launch of Biome Acne™ in late March 2022. These 2 new products,
together with 3 other probiotic products launched since IPO in November 2021
(Biome Her™, Biome Eczema™ and Biome Advanced™ 10 pack) accounted for 22%
of June quarter sales.
Distribution network
During the quarter Biome secured a material distribution agreement with Priceline
Pharmacy Group, for distribution of its Activated Probiotics® range. This agreement
expands the Company’s distribution by 370 high volume service-focused
pharmacies, taking the distribution footprint to circa 3,000 outlets. The agreement
also strengthens Biome’s existing relationship with Wesfarmers owned Australian
Pharmaceutical Industries (API). Biome expects the initial allocation of the Activated
Probiotics® products into Priceline Pharmacies around Australia in July 2022.
Biome Australia’s Managing Director and Founder, Blair Norfolk commented:
“I am pleased to report that FY22 was a strong year for Biome and its flagship
brand, Activated Probiotics. Biome closed the year with a record quarter sales of
$1.39m, unaudited, and another notable year of growth for the company — up 78%
on FY21. I am thrilled to see the development of sales and the number of our
probiotic products getting into the hands of Australians every day through both
community pharmacy and independent health practitioners. Biome's products
have the potential to make a meaningful difference in the quality of life of patients.
The feedback and testimonials that we continue to receive from Biome's health
practitioner partners is inspiring. As we begin FY23 we will commence our new
partnership with Priceline Pharmacy, adding 370 high volume pharmacies to our
national distribution network and ability to reach more patients around Australia.”
Company Financial and Corporate Overview
Cash at the end of the quarter was $5.5 million (31 March 2022: $6.6 million).
In Q4 the Company received $1,367,726 (previous quarter $711,104) in cash receipts
from customers.
Net cash outflow from operating activities for the quarter was $1.0 million (previous
quarter net cash outflow of $1.11 million). Business activities expenditure totalled
$2.37 million for the June quarter (an increase of 30% from the previous quarter of
$1.82 million), consisting of advertising and marketing of $370,000 (previous quarter
$204,000), operating costs of $1,064,000 (previous quarter $789,000) and research
and development of $58,000 (previous quarter $51,000) with the balance of
operating outflows being administration, staff costs and FBT totalling $898,000
(previous quarter $775,000). The Company received $14,000 in Export Market
Development Grants (EMDG) during the June quarter.
The table below illustrates the expenditure comparison against the
Company’s ‘Use of proceeds table’ in the Prospectus dated 19 October 2021:
Use of proceeds
Amounted budgeted in
Prospectus
Actual amount spent
to date
Inventory
$2.4 million
$0.5 million
Sales & Marketing
$2.15 million
$0.62 million
New Product Development
$0.5 million
$0.12 million
Administrative & Working
Capital
$1.95 million
$0.19 million
Costs of the Offer
$1 million
$1.07 million
Total
$8 million
$2.5 million
Table 1: Use of funds
The Company notes that in the June 2022 quarter, the Company paid $120k to
Directors of the Company in fees, salaries and superannuation.
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
BIOME AUSTRALIA LIMITED (BIO)
ABN
Quarter ended (“current quarter”)
51 627 364 014
JUNE 2022
Consolidated statement of cash flows
Current quarter $A’000
Year to date
(....12...months)
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
1,368
4,028
(58)
(162)
(1,064)
(3,367)
(370)
(1,047)
(a)
research and development
(b)
product manufacturing and operating
costs
(c)
advertising and marketing
(d)
leased assets
(e)
staff costs
(678)
(2,461)
(f)
administration and corporate costs
(216)
(705)
-
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
1
2
1.5
Interest and other costs of finance paid
-
(24)
1.6
Income taxes & FBT paid
(4)
(8)
1.7
Government grants and tax incentives
14
270
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating activities
(1,007)
(3,474)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
2.2
(a)
entities
-
-
(b)
businesses
-
-
(c)
property, plant and equipment
-
-
(d)
investments
-
-
(e)
intellectual property
-
-
(f)
other non-current assets
(*leasehold improvements)
(109)
(128)
Proceeds from disposal of:
(a)
entities
(b)
businesses
-
-
(c)
property, plant and equipment
-
32
(d)
investments
-
-
(e)
intellectual property
-
-
(f)
other non-current assets
-
-
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (**bank guarantee)
-
(30)
2.6
Net cash from / (used in) investing
activities
(109)
(126)
-
9,797
Cash flows from financing activities
3.
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of equity
securities or convertible debt securities
-
(1,236)
3.5
Proceeds from borrowings
-
170
3.6
Repayment of borrowings
-
(242)
3.7
Transaction costs related to loans and
borrowings
-
(1)
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
0
8,488
4.
Net increase / (decrease) in cash and cash
equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
6,613
610
4.2
Net cash from / (used in) operating activities
(item 1.9 above)
(1,007)
(3,474)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(109)
(126)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
0
8,488
4.5
Effect of movement in exchange rates on
cash held
(5)
(6)
4.6
Cash and cash equivalents at end of
period
5,492
5,492
5.
Reconciliation of cash and cash equivalents
Current quarter
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
$A’000
related items in the accounts
5.1
Bank balances
5.2
Previous quarter
$A’000
5,492
6,613
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of quarter
(should equal item 4.6 above)
5,492
6,613
6.
Payments to related parties of the entity and their associates
Current quarter
$A'000
6.1
Aggregate amount of payments to related parties and their associates
included in item 1
120
6.2
Aggregate amount of payments to related parties and their associates
included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments.
7.
Financing facilities
Total facility amount at Amount drawn at
Note: the term “facility’ includes all forms of
quarter end
financing arrangements available to the entity. quarter end
Add notes as necessary for an understanding of
$A’000
$A’000
the sources of finance available to the entity.
7.1
Loan facilities
Nil
n/a
7.2
Credit standby arrangements
Nil
n/a
7.3
Other (please specify)
Nil
n/a
7.4
Total financing facilities
Nil
n/a
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest rate, maturity
date and whether it is secured or unsecured. If any additional financing facilities have been entered
into or are proposed to be entered into after quarter end, include a note providing details of those
facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(1,002)
8.2
Cash and cash equivalents at quarter end (item 4.6)
5,492
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by item 8.1)
n/a
$A’000
5,492
5.5
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”.
Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
n/a
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
n/a
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
n/a
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above
must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
26 JULY 2022
Authorised by: By the Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market
about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position.
An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the
definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report
has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing
activities, depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By
the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here:
“By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold
yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance
Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion,
the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting
standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis
of a sound system of risk management and internal control which is operating effectively.
-ENDS-
Approved for release by the Biome Australia board of directors.
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-based
live biotherapeutics (probiotics) and complementary medicines, many of which are
supported by clinical research. Biome aims to improve health outcomes and quality of life,
and make its products accessible to all.
Biome distributes its products in Australia, New Zealand and the United Kingdom. In
partnership with some of the world's leading organisations in microbiome research and
development, Biome has developed a range of unique live biotherapeutic (probiotic)
products with innovative delivery technologies that improve their stability and efficacy to
create its flagship range of complementary medicines: Activated Probiotics®.
Supported by clinical research, including randomised double-blind placebo-controlled trials,
Activated Probiotics help prevent and support the management of various health concerns,
including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS.
Through practitioner-only distribution, Biome is committed to educating health professionals
on the newfound systemic health effects of the gut microbiota, helping them to provide
innovative, evidence-based natural medicines for the management of some of humanity's
most prevalent and chronic health concerns.
Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical
range, Activated Nutrients® and a sports performance and recovery range, Activated X
Performance®, which is made exclusively for professional athletes.
For more information visit: www.biomeaustralia.com
Investor Relations
WE Communications
Hannah Howlett
+61 450 648 064
hhowlett@we-worldwide.com
Media enquiries
media@activated.co
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon as an
indication or guarantee of future performance. Actual results, performance or achievements may
differ materially from those expressed or implied in such Forward Looking Statements and any
projections and assumptions on which these Forward Looking Statements are based. Such statements
may assume the success of Biome's business strategies. You are cautioned not to place undue reliance
on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of this
release. Any Forward Looking Statements containing forward looking financial information provided in
this release is for illustrative purposes only and is not represented as being indicative of Biome's views
on its future financial condition and/or performance. The historic financial information for the
September 2021 financial quarter and revenue figures for October and November 2021 have not been
audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future
performance.
Nothing in this release is a promise or representation as to the future. No representation or warranty,
express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
Forward Looking Statements contained in this release. Except as required by law or regulation
(including the ASX Listing Rules), Biome does not undertake to provide any additional or updated
information whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness, currency,
accuracy, reliability or completeness of information in this release or the accuracy, likelihood of
achievement or reasonableness of any Forward Looking Statements (or any event or results expressed
or implied in any Forward Looking Statements) contained in, implied by, the information in this release
or any part of it, or that this release contains all material information about Biome or which a
prospective investor or purchaser may require in evaluating a possible investment in Biome or
acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Share your feedback
Discover